ADC Therapeutics SA (ADCT) - Total Liabilities
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has total liabilities worth $507.87 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ADC Therapeutics SA - Total Liabilities Trend (2016–2025)
This chart illustrates how ADC Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. See ADCT working capital ratio to evaluate short-term liquidity relative to the company's equity base.
ADC Therapeutics SA Competitors by Total Liabilities
The table below lists competitors of ADC Therapeutics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alldigi Tech Limited
NSE:ALLDIGI
|
India | Rs1.65 Billion |
|
Clal Industries and Beverages Ltd
TA:CLBV
|
Israel | ILA309.55 Million |
|
FDC International Hotels Corp
TW:2748
|
Taiwan | NT$1.95 Billion |
|
Muhak Co. Ltd
KO:033920
|
Korea | ₩105.07 Billion |
|
SPRINGFIELD PROP. LS-125
F:9MZ
|
Germany | €145.51 Million |
|
Merit Turizm Yatirim ve Isletme AS
IS:MERIT
|
Turkey | TL40.94 Million |
|
China Electric Manufacturing Corp
TW:1611
|
Taiwan | NT$1.28 Billion |
|
Kross Ltd
NSE:KROSS
|
India | Rs1.49 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down ADC Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ADCT company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ADC Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ADC Therapeutics SA (2016–2025)
The table below shows the annual total liabilities of ADC Therapeutics SA from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $508.98 Million | -2.98% |
| 2024-12-31 | $524.62 Million | +4.29% |
| 2023-12-31 | $503.03 Million | +22.27% |
| 2022-12-31 | $411.41 Million | -8.96% |
| 2021-12-31 | $451.88 Million | +153.60% |
| 2020-12-31 | $178.19 Million | +571.74% |
| 2019-12-31 | $26.53 Million | +9.09% |
| 2018-12-31 | $24.32 Million | +6.72% |
| 2017-12-31 | $22.78 Million | +60.64% |
| 2016-12-31 | $14.18 Million | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more